Symphogen obtains milestone payment from Merck under Sym004 research deal
The two antibodies present in the investigational candidate were designed to block ligand binding, receptor activation and downstream signaling in addition to extracting the removal of the EGFR
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.